BILLERICA, Mass., Apr 29, 2010 (BUSINESS WIRE) --Bruker Corporation (NASDAQ: BRKR) today reported financial results for
the first quarter ended March 31, 2010.
Q1 GAAP Highlights
|
|
|
|
|
|
Q1-2010
|
|
|
|
|
|
Q1-2009
|
|
|
|
|
|
Growth
|
Revenue
|
|
|
|
|
|
$
|
277.7M
|
|
|
|
|
|
$
|
230.5M
|
|
|
|
|
|
+20.5%
|
Operating Income
|
|
|
|
|
|
$
|
26.9M
|
|
|
|
|
|
$
|
14.3M
|
|
|
|
|
|
+88.1%
|
EPS
|
|
|
|
|
|
$
|
0.10
|
|
|
|
|
|
$
|
0.05
|
|
|
|
|
|
+100%
|
Financial Results
In the first quarter of 2010, Bruker's revenue was $277.7 million, an
increase of 20.5% compared to revenue of $230.5 in the first quarter of
2009. Excluding the effects of foreign currency translation, first
quarter 2010 revenue increased by 12.4% year-over-year. In the first
quarter of 2010, GAAP revenue increased by 16.4% year-over-year for the
Bruker Scientific Instruments (BSI) segment, and by 156% year-over-year
for the Bruker Energy & Supercon Technologies (BEST) segment.
Bruker's operating income in the first quarter of 2010 was $26.9
million, compared to $14.3 million in the first quarter of 2009. GAAP
operating margin for the BSI segment in the first quarter of 2010 was
10.6%, compared to 7.2% in the first quarter of 2009.
Bruker's GAAP net income for the first quarter of 2010 was $16.1
million, or $0.10 per diluted share, compared to net income of $8.4
million, or $0.05 per diluted share, in the first quarter of 2009.
Included in Bruker's earnings per share (EPS) for the first quarter 2010
was non-cash stock-based compensation expense of ($0.01) per diluted
share, the same as in the first quarter of 2009. EPS for the BSI segment
in the first quarter of 2010 was $0.10, compared to $0.06 in the first
quarter of 2009. EPS for the first quarter of 2010 for the BEST segment
was $0.00, compared to a loss of ($0.02) in the first quarter of 2009.
Bruker cash flow from operations for the first quarter 2010 was $5.5
million, compared to $13.1 million in the first quarter of 2009. Bruker
ended the first quarter of 2010 with cash, cash equivalents and
restricted cash of $206.6 million, and net cash of $73.4 million.
Comment and Outlook
Frank Laukien, President and CEO, commented: "We are very pleased with
our first quarter 2010 results, with strong year-over-year revenue
growth and significant improvements in gross and operating margins. All
four operating divisions in our BSI segment delivered double-digit
growth year-over-year, and our BEST segment had triple-digit growth for
the second quarter in a row. The industrial and applied markets
continued to improve gradually during the first quarter, and overall we
recorded healthy new order bookings, including more than $10 million in
additional U.S. stimulus orders, all of which contributed to strong
backlog at the end of the first quarter."
EARNINGS CONFERENCE CALL
Bruker Corporation will host an operator-assisted earnings conference
call at 9:00 a.m. Eastern Daylight Time on Thursday, April 29, 2010. To
listen to the webcast, investors can go to http://ir.bruker.com
and click on the live web broadcast symbol. The webcast will be
available through the Company web site for 30 days. Investors can also
listen and participate on the telephone in the US and Canada by calling
800-688-0796, or +1-617-614-4070 outside the US and Canada. Investors
should refer to the Bruker Earnings Call. A telephone replay of the
conference call will be available one hour after the conference call by
dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside
the US and Canada, and then entering replay pass code 62891829. For more
information, please visit http://ir.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this presentation that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in our
filings with the Securities and Exchange Commission. These and other
factors are identified and described in more detail in our filings with
the SEC, including, without limitation, our annual report on Form 10-K
for the year ended December 31, 2009, our most recent quarterly reports
on Form 10-Q and our current reports on Form 8-K. We expressly disclaim
any intent or obligation to update these forward-looking statements
other than as required by law.
|
Bruker Corporation
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
|
(in millions, except per share data)
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2010 |
|
|
|
2009 |
|
|
|
|
|
|
Product revenue
|
|
$
|
244.0
|
|
|
$
|
202.2
|
Service revenue
|
|
|
31.5
|
|
|
|
26.9
|
Other revenue
|
|
|
2.2
|
|
|
|
1.4
|
|
Total revenue
|
|
|
277.7
|
|
|
|
230.5
|
|
|
|
|
|
|
Cost of product revenue
|
|
|
134.2
|
|
|
|
111.7
|
Cost of service revenue
|
|
|
17.2
|
|
|
|
16.1
|
|
Total cost of revenue
|
|
|
151.4
|
|
|
|
127.8
|
|
|
|
|
|
|
|
Gross profit
|
|
|
126.3
|
|
|
|
102.7
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
Sales and marketing
|
|
|
49.1
|
|
|
|
42.6
|
General and administrative
|
|
|
17.0
|
|
|
|
16.3
|
Research and development
|
|
|
32.8
|
|
|
|
29.1
|
Restructuring and acquisition-related charges
|
|
|
0.5
|
|
|
|
0.4
|
|
Total operating expenses
|
|
|
99.4
|
|
|
|
88.4
|
|
|
|
|
|
|
|
Operating income
|
|
|
26.9
|
|
|
|
14.3
|
|
|
|
|
|
|
Interest and other income (expense), net
|
|
|
(0.3
|
)
|
|
|
0.1
|
|
|
|
|
|
|
Income before income taxes and noncontrolling
|
|
|
|
|
|
interest in consolidated subsidiaries
|
|
|
26.6
|
|
|
|
14.4
|
Income tax provision
|
|
|
10.6
|
|
|
|
5.8
|
|
|
|
|
|
|
Consolidated net income
|
|
|
16.0
|
|
|
|
8.6
|
Net income (loss) attributable to noncontrolling
|
|
|
|
|
interests in consolidated subsidiaries
|
|
|
(0.1
|
)
|
|
|
0.2
|
Net income attributable to Bruker Corporation
|
|
$
|
16.1
|
|
|
$
|
8.4
|
|
|
|
|
|
|
Net income per common share attributable to
|
|
|
|
|
|
Bruker Corporation shareholders:
|
|
|
|
|
|
Basic and diluted
|
|
$
|
0.10
|
|
|
$
|
0.05
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
Basic
|
|
|
164.1
|
|
|
|
163.3
|
|
Diluted
|
|
|
165.6
|
|
|
|
164.3
|
|
Bruker Corporation
|
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
|
(in millions)
|
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
|
|
|
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash, cash equivalents and restricted cash
|
|
$
|
206.6
|
|
$
|
209.1
|
|
Accounts receivable, net
|
|
|
174.9
|
|
|
184.1
|
|
Inventories
|
|
|
431.2
|
|
|
422.8
|
|
Other current assets
|
|
|
61.6
|
|
|
57.5
|
|
|
Total current assets
|
|
|
874.3
|
|
|
873.5
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
212.0
|
|
|
223.4
|
Intangible and other long-term assets
|
|
|
73.3
|
|
|
75.1
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,159.6
|
|
$
|
1,172.0
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Short-term borrowings
|
|
$
|
23.6
|
|
$
|
22.0
|
|
Accounts payable
|
|
|
53.7
|
|
|
49.8
|
|
Customer advances
|
|
|
218.3
|
|
|
219.2
|
|
Other current liabilities
|
|
|
248.4
|
|
|
249.2
|
|
|
Total current liabilities
|
|
|
544.0
|
|
|
540.2
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
109.6
|
|
|
114.6
|
Other long-term liabilities
|
|
|
88.1
|
|
|
98.4
|
|
|
|
|
|
|
|
Total shareholders' equity
|
|
|
417.9
|
|
|
418.8
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
$
|
1,159.6
|
|
$
|
1,172.0
|
|
Reconciliation of BSI and BEST reportable segments to the
consolidated results of Bruker
|
Corporation for the quarters ended March 31, 2010 and 2009
(unaudited)
|
(in millions, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker |
|
|
|
|
|
|
Bruker |
|
Energy & |
|
Corporate, |
|
Consolidated |
|
|
Scientific |
|
Supercon |
|
Adjustments |
|
Bruker |
March 31, 2010: |
|
Instruments |
|
Technologies |
|
& Eliminations |
|
Corporation |
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
260.3
|
|
|
$
|
20.7
|
|
|
$
|
(3.3
|
)
|
|
$
|
277.7
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
122.5
|
|
|
|
4.1
|
|
|
|
(0.3
|
)
|
|
|
126.3
|
|
Gross profit margin
|
|
|
47.1
|
%
|
|
|
19.8
|
%
|
|
|
|
|
45.5
|
%
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
27.7
|
|
|
|
(0.5
|
)
|
|
|
(0.3
|
)
|
|
|
26.9
|
|
Operating margin
|
|
|
10.6
|
%
|
|
|
(2.4
|
%)
|
|
|
|
|
9.7
|
%
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
to Bruker Corporation
|
|
|
17.2
|
|
|
|
(0.8
|
)
|
|
|
(0.3
|
)
|
|
|
16.1
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common
|
|
|
|
|
|
|
|
|
share attributable to Bruker Corporation
|
|
$
|
0.10
|
|
|
$
|
(0.00
|
)
|
|
|
|
$
|
0.10
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
165.6
|
|
|
|
164.1
|
|
|
|
|
|
165.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2009: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
223.6
|
|
|
$
|
8.1
|
|
|
$
|
(1.2
|
)
|
|
$
|
230.5
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
101.4
|
|
|
|
0.7
|
|
|
|
0.6
|
|
|
|
102.7
|
|
Gross profit margin
|
|
|
45.3
|
%
|
|
|
8.6
|
%
|
|
|
|
|
44.6
|
%
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
16.1
|
|
|
|
(2.4
|
)
|
|
|
0.6
|
|
|
|
14.3
|
|
Operating margin
|
|
|
7.2
|
%
|
|
|
(29.6
|
%)
|
|
|
|
|
6.2
|
%
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
to Bruker Corporation
|
|
|
10.2
|
|
|
|
(2.6
|
)
|
|
|
0.8
|
|
|
|
8.4
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common
|
|
|
|
|
|
|
|
|
share attributable to Bruker Corporation
|
|
$
|
0.06
|
|
|
$
|
(0.02
|
)
|
|
|
|
$
|
0.05
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
164.3
|
|
|
|
163.3
|
|
|
|
|
|
164.3
|
|
SOURCE: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1 978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com